MORGAN STANLEY PLC/CALL/AMGEN/310/0.1/21.06.24 | Market Closed - Börse Stuttgart 02:32:55 2024-05-31 pm EDT | ||
| 0.4 EUR | +11.11% |
|
| 1 month | +97.04% | ||
| 3 months | +8.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.4 | +11.11% |
| 24-05-30 | 0.36 | +59.29% |
| 24-05-29 | 0.226 | -60.35% |
| 24-05-28 | 0.57 | -5.00% |
| 24-05-27 | 0.6 | +13.21% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 02:32 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MD7BV6 |
| ISIN | DE000MD7BV66 |
| Date issued | 2022-08-24 |
| Strike | 310 $ |
| Maturity | 2024-06-21 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.51 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.03 € |
| Spread % | 6.25% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
